<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877796</url>
  </required_header>
  <id_info>
    <org_study_id>2X-1000</org_study_id>
    <nct_id>NCT03877796</nct_id>
  </id_info>
  <brief_title>Clinical Pre-screening Protocol for Ovarian Cancer</brief_title>
  <official_title>Clinical Pre-screening Protocol for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Venture</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncology Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pre-screening study is established to pre-screen tumor samples from ovarian cancer
      patients to identify if they, at a later stage of their disease, will benefit from treatment
      with any investigational cancer drugs available to Oncology Venture, when these drugs are
      approved for future clinical studies by local authorities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug</measure>
    <time_frame>up to 2 years</time_frame>
    <description>based on FFPE ovarian cancer tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer patients</arm_group_label>
    <description>with formalin-fixed paraffin-embedded (FFPE) tumor tissue available</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Response PredictorÂ® (DRP)</intervention_name>
    <description>A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.</description>
    <arm_group_label>Ovarian cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with archival ovarian cancer tumor tissue is collected for measurement using mRNA or
      microRNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be identified at their already planned treatment and or at control visits at
        the oncology department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological confirmed epithelia ovarian cancer

          -  Relapse after 2 or more chemotherapies for ovarian cancer

          -  FFPE tumor tissue available

        Exclusion Criteria:

          -  Other primary malignancy within the last 5 years prior to enrolment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christin Whalen, MD</last_name>
    <phone>+617-582-7738</phone>
    <email>christin_whalen@DFCI.HARVARD.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

